Posaconazole in Aspergillosis

A balanced guide for patients and clinicians

Posaconazole is a broad-spectrum triazole antifungal used in:

  • Chronic pulmonary aspergillosis (CPA)

  • Allergic bronchopulmonary aspergillosis (ABPA) (selected or refractory cases)

  • Invasive aspergillosis

  • Patients intolerant of itraconazole or voriconazole

  • Antifungal prophylaxis in high-risk immunocompromised patients

It is generally well tolerated and often used when other azoles cause side effects.

1️⃣ What Posaconazole Does

Like other azoles, posaconazole blocks fungal ergosterol synthesis (CYP51 inhibition), preventing fungal growth.

It:

  • Suppresses Aspergillus replication

  • Reduces fungal burden

  • Helps stabilise lung disease in CPA

  • Can reduce steroid need in some ABPA cases

It works gradually over weeks.

2️⃣ How Long Is Treatment?

In CPA

  • Often 6–12 months or longer

  • Sometimes long-term suppressive therapy

  • Used if other azoles are ineffective or not tolerated

In ABPA

  • Used in refractory or steroid-dependent disease

In prophylaxis

  • Duration depends on immune suppression status

As with other azoles, premature discontinuation may lead to relapse.

3️⃣ Formulations Matter

Posaconazole comes in:

  • Delayed-release tablets

  • Oral suspension

  • Intravenous formulation

Tablets (preferred)

  • Good, reliable absorption

  • Less affected by food

  • More predictable levels

Oral suspension

  • Absorption highly dependent on food (especially fatty meals)

  • Greater variability

In most CPA practice, tablets are preferred.

4️⃣ Why Blood Level Monitoring Is Still Important

Posaconazole has more predictable pharmacokinetics than itraconazole or voriconazole, but monitoring is still recommended.

Reasons:

  • Interpatient variability

  • Drug interactions

  • Severe infection requires adequate exposure

  • Toxicity avoidance

If Levels Are Too Low

  • Inadequate fungal suppression

  • Ongoing disease activity

  • Risk of resistance

If Levels Are Too High

  • Liver abnormalities

  • Gastrointestinal symptoms

  • Rare cardiac effects

Typical Target (Trough)

  • 1 mg/L for treatment

  • 0.7 mg/L often sufficient for prophylaxis

(Laboratory guidance varies.)

Levels are typically checked:

  • After 5–7 days

  • After dose adjustments

  • If response is suboptimal

  • If toxicity suspected

5️⃣ Common Side Effects (Usually Mild)

  • Nausea

  • Diarrhoea

  • Abdominal discomfort

  • Headache

These are often less troublesome than with voriconazole.

6️⃣ Less Common but Important Effects

Liver Abnormalities

Routine monitoring required.

Most are mild and reversible.

QT Interval Prolongation

Posaconazole can prolong QT interval.

Caution in patients with:

  • Known arrhythmias

  • Electrolyte imbalance

  • Other QT-prolonging drugs

ECG monitoring may be appropriate in higher-risk individuals.

Hypertension & Mineralocorticoid Effect (Rare)

High levels can rarely cause:

  • Elevated blood pressure

  • Low potassium

More common with long-term or high exposure.

Neuropathy

Much less commonly reported than with other azoles, but peripheral symptoms should still be assessed carefully if they occur.

7️⃣ Food & Drug Advice

  • Tablets: can be taken with or without food (follow prescribing guidance)

  • Suspension: take with food (preferably fatty meal)

Avoid:

  • Grapefruit

  • St John’s Wort

Posaconazole inhibits CYP3A4 and interacts with:

  • Statins

  • Certain immunosuppressants

  • Some anticoagulants

Medication review is essential.

8️⃣ Comparison Snapshot

Feature Itraconazole Voriconazole Posaconazole
Absorption variability High Moderate Low–Moderate (tablet)
Visual side effects Rare Common Rare
Photosensitivity Rare Common Rare
QT prolongation Minimal Possible Possible
TDM needed Yes Essential Recommended
Long-term tolerability Moderate Sometimes limited Often good

Balanced Summary for Patients

Posaconazole is a newer azole that is often well tolerated and provides reliable antifungal coverage. Blood tests help ensure the level is effective and safe. Most patients complete treatment without major difficulties.

Clinician Checklist

  • Confirm formulation (tablet preferred in CPA)

  • Baseline LFTs

  • Review ECG if cardiac risk present

  • Check electrolytes (especially potassium)

  • Arrange trough level after initiation

  • Review full medication list

by GAtherton

Voriconazole in Aspergillosis

A balanced guide for patients and clinicians

Voriconazole is a broad-spectrum triazole antifungal used in:

  • Chronic pulmonary aspergillosis (CPA)

  • Allergic bronchopulmonary aspergillosis (ABPA) (selected cases)

  • Invasive aspergillosis

  • Azole-resistant or itraconazole-intolerant cases

It is available orally and intravenously and is often used when a stronger or more reliably absorbed azole is required.

1️⃣ What Voriconazole Does

Voriconazole works by blocking fungal ergosterol synthesis (CYP51 inhibition), which disrupts the fungal cell membrane.

Compared with itraconazole:

  • More potent against Aspergillus

  • More predictable oral absorption

  • More central nervous system penetration

It often produces symptom improvement over weeks, though some effects (e.g. visual symptoms) may occur quickly.

2️⃣ How Long Is Treatment?

In CPA

  • Often 6–12 months or longer

  • Sometimes used as second-line or after intolerance to itraconazole

  • Long-term suppressive therapy may be required

In ABPA

  • Used in selected steroid-dependent or refractory cases

In invasive disease

  • Typically several months depending on response and immune status

3️⃣ Why Blood Level Monitoring Is Essential

Voriconazole has non-linear pharmacokinetics.

Small dose changes can cause large blood level shifts.

Two patients on the same dose may have very different levels due to:

  • Liver metabolism (CYP2C19 genetic variation is important)

  • Drug interactions

  • Age

  • Weight

  • Liver function

If Levels Are Too Low

  • Treatment failure

  • Persistent fungal activity

  • Risk of resistance

If Levels Are Too High

  • Liver toxicity

  • Neurological side effects

  • Visual disturbances

  • Increased interaction risk

Typical Target (Trough)

  • Generally 1–5.5 mg/L (lab dependent)

  • Toxicity risk increases >5–6 mg/L

Levels are usually checked:

  • 5–7 days after starting

  • After dose adjustments

  • If side effects occur

  • If clinical response is inadequate

4️⃣ Common Side Effects (Often Mild & Reversible)

Visual Disturbances (Very Common but Usually Harmless)

  • Blurred vision

  • Altered colour perception

  • Light sensitivity

  • “Wavy” vision

These typically:

  • Occur within 30–60 minutes of dosing

  • Last less than an hour

  • Reduce over time

Patients should avoid night driving initially until they understand their response.

Photosensitivity

  • Increased sensitivity to sunlight

  • Sunburn risk

  • Long-term risk of skin damage with prolonged therapy

Sun protection is important.

Gastrointestinal

  • Nausea

  • Abdominal discomfort

5️⃣ Less Common but Important Effects

Neurological

  • Headache

  • Vivid dreams

  • Hallucinations (usually at high levels)

  • Confusion (dose-related)

These are generally reversible with dose adjustment.

Liver Abnormalities

Routine liver function monitoring is required.

Most abnormalities are mild and resolve with dose modification.

Cardiac Effects

Voriconazole can prolong the QT interval.

Caution in patients with:

  • Known arrhythmias

  • Electrolyte imbalance

  • Other QT-prolonging drugs

ECG monitoring may be appropriate in higher-risk patients.

Skin Cancer Risk (Long-Term Use)

With prolonged use (especially >1–2 years):

  • Increased risk of skin squamous cell carcinoma

  • Particularly in transplant recipients

Sun protection and dermatology review are advised for long-term therapy.

6️⃣ Food & Drug Advice

  • Avoid grapefruit

  • Avoid St John’s Wort

  • Take tablets at least 1 hour before or after meals (food reduces absorption)

Voriconazole has many CYP-mediated interactions and requires careful medication review.

7️⃣ Comparison With Itraconazole (Simple Overview)

Feature Itraconazole Voriconazole
Absorption variability High More predictable
Visual side effects Rare Common but mild
Photosensitivity Rare More common
QT prolongation Minimal Possible
TDM needed Yes Yes (essential)

Balanced Summary for Patients

Voriconazole is a strong antifungal used when more reliable or potent treatment is needed. Most side effects are manageable and reversible, and blood monitoring keeps treatment safe.

Clinician Checklist

  • Confirm indication and prior azole exposure

  • Check baseline LFTs

  • Review ECG if cardiac risk present

  • Assess drug interactions (CYP2C19, 2C9, 3A4)

  • Arrange trough level at day 5–7

  • Counsel regarding visual symptoms and sun protection

by GAtherton

🧬 How Biologics Are Reshaping Our Understanding of ABPA Subtypes

For many years, Allergic Bronchopulmonary Aspergillosis (ABPA) was viewed as a single condition:

An allergic reaction to Aspergillus fumigatus in the lungs, treated primarily with steroids and sometimes antifungal medication.

Biologic therapies are changing that picture.

They are not just new treatments — they are helping us understand that ABPA may not be one uniform disease, but a spectrum of related inflammatory patterns.

🧠 The Traditional View of ABPA

Historically, ABPA has been defined by:

  • Asthma (or cystic fibrosis)

  • High total IgE

  • Sensitisation to Aspergillus

  • Raised eosinophils

  • Characteristic CT changes (e.g. bronchiectasis, mucus plugging)

The dominant biological explanation was:

A Type 2 (allergic) immune overreaction driven by eosinophils and IgE.

Steroids were used to suppress this immune response.

This model assumed that most patients had broadly similar immune drivers.

💊 What Are Biologics?

Biologics are targeted antibody therapies designed to block specific immune pathways.

In asthma and ABPA, the main targets are:

  • IL-5 (drives eosinophils)

  • IL-5 receptor

  • IL-4 / IL-13 (drive allergic inflammation)

  • IgE

Examples include:

  • Anti–IL-5 therapies (e.g. mepolizumab, benralizumab)

  • Anti–IL-4/IL-13 therapy (e.g. dupilumab)

  • Anti-IgE therapy (e.g. omalizumab)

Instead of broadly suppressing immunity like steroids, they selectively block parts of the allergic pathway.

🔍 What Biologics Are Teaching Us

As biologics have been used in ABPA (often off-label or in specialist centres), an interesting pattern has emerged:

Not all ABPA behaves the same way.

Some patients respond dramatically to anti–IL-5 therapy.
Others respond better to anti–IL-4/IL-13 therapy.
Some show strong IgE-driven disease.
Others appear more mucus-dominant.

This suggests that ABPA may include different inflammatory endotypes (biological subtypes), even if outward symptoms look similar.

🧩 Possible Emerging ABPA Subtypes

While research is ongoing, clinicians are beginning to recognise patterns such as:

1️⃣ Strongly Eosinophilic-Dominant ABPA

  • Very high eosinophils

  • Frequent exacerbations

  • Often responds well to IL-5 blockade

2️⃣ IgE-Heavy Allergic ABPA

  • Extremely high total IgE

  • Prominent allergic features

  • May respond to anti-IgE therapy

3️⃣ Mucus-Plug Dominant ABPA

  • Recurrent thick mucus impaction

  • Radiological plugging

  • May involve additional inflammatory drivers

4️⃣ Steroid-Dependent ABPA

  • Relapses when steroids reduced

  • Biologics may allow steroid-sparing strategies

These patterns are not yet formal categories, but biologics are revealing that ABPA is biologically more complex than once thought.

🧪 Blood Eosinophils vs Airway Inflammation

Biologics have also highlighted another key insight:

Blood eosinophil levels do not always perfectly reflect what is happening in the lungs.

Some patients:

  • Have modest blood eosinophils

  • But still show eosinophilic airway activity

Biologic response patterns are helping refine how we interpret these markers.

🧠 Moving From “Diagnosis” to “Endotype”

Traditionally, medicine focused on:

Diagnosis (ABPA vs not ABPA)

Biologics are pushing us toward:

Endotype (which immune pathway is dominant in this patient?)

This matters because targeted therapy works best when matched to the dominant pathway.

In future, ABPA may be classified not just by clinical features, but by molecular drivers.

🫁 What This Means for Patients

Biologics offer:

  • Reduced steroid dependence

  • Fewer exacerbations

  • Improved lung function in selected patients

  • Potential improvement in mucus burden

But they also help answer deeper questions:

  • Why do some patients relapse frequently?

  • Why do some have extreme eosinophilia?

  • Why do others have more mucus plugging than inflammation?

They are helping personalise ABPA care.

⚖ Important Caveats

  • Biologics are not currently licensed specifically for ABPA in many countries.

  • Evidence is growing but still developing.

  • They are usually considered in specialist centres.

  • They are not appropriate for every patient.

Steroids and antifungals remain core treatments.

🔭 The Future

Over the next decade, we may see:

  • Better classification of ABPA subtypes

  • Biomarker-guided treatment selection

  • Reduced long-term steroid exposure

  • Improved understanding of mucus plug biology

  • Trials specifically designed for ABPA (rather than extrapolated from asthma)

Biologics are not just new drugs.

They are acting as scientific tools that are reshaping how we think about ABPA itself.

🧠 Key Takeaway

ABPA is no longer seen as one single uniform allergic condition.

Biologic therapies are revealing that:

ABPA is likely a spectrum of related inflammatory patterns — and treatment may increasingly be tailored to the dominant pathway in each individual.

References

Agarwal R, Sehgal IS, Muthu V, Denning DW, Chakrabarti A, Soundappan K, Garg M, Rudramurthy SM, Dhooria S, Armstrong-James D, Asano K, Gangneux JP, Chotirmall SH, Salzer HJF, Chalmers JD, Godet C, Joest M, Page I, Nair P, Arjun P, Dhar R, Jat KR, Joe G, Krishnaswamy UM, Mathew JL, Maturu VN, Mohan A, Nath A, Patel D, Savio J, Saxena P, Soman R, Thangakunam B, Baxter CG, Bongomin F, Calhoun WJ, Cornely OA, Douglass JA, Kosmidis C, Meis JF, Moss R, Pasqualotto AC, Seidel D, Sprute R, Prasad KT, Aggarwal AN. Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis/mycoses. Eur Respir J. 2024 Apr 4;63(4):2400061. doi: 10.1183/13993003.00061-2024. PMID: 38423624; PMCID: PMC10991853.

by GAtherton

Systemic fungal infections: why speed, diagnosis and stewardship matter

Systemic fungal infections — including aspergillosis, candidiasis, cryptococcosis, mucormycosis and pneumocystis pneumonia — are medical emergencies. When diagnosis or treatment is delayed, mortality rises sharply. This comprehensive review brings together current understanding of how these infections arise, why they are so difficult to diagnose, and what is needed to improve outcomes.

Why fungal infections are often missed

Unlike many bacterial infections, systemic fungal infections can be hard to confirm quickly. Fungal organisms are often present in low numbers, may be released intermittently into the bloodstream, and can be difficult to grow in standard cultures. As a result, no single test is usually sufficient, and clinicians often need a combination of imaging, cultures, antigen tests, molecular tests (PCR), and histopathology.

Because delay can be fatal, antifungal treatment is frequently started on clinical suspicion alone — especially in critically ill or immunocompromised patients. The paper emphasises that this approach is often necessary, but it must be paired with a clear diagnostic strategy.

Antifungal stewardship: knowing when to stop

A central message of the paper is that diagnostic tests are just as important for stopping treatment as for starting it. Antifungal drugs can be toxic, interact with many other medicines, and drive antifungal resistance if used unnecessarily.

The authors stress that:

  • Diagnostic results should be actively reviewed

  • Antifungal therapy should be stopped or stepped down if infection is not supported by evidence

  • This approach protects patients and preserves antifungal effectiveness

Antifungal resistance is a growing threat

Antifungal resistance is no longer rare. The review highlights:

  • Azole resistance in Aspergillus, including cryptic species

  • Rising resistance in several Candida species

  • The global spread of multidrug-resistant Candida auris

Because of this, the authors recommend that all clinically relevant fungal isolates are identified to species level and tested for antifungal susceptibility wherever possible. Making assumptions about drug sensitivity is increasingly unsafe.

Aspergillosis: a broad spectrum of disease

The paper clearly outlines the many forms of aspergillosis, ranging from:

  • Allergic disease (such as allergic bronchopulmonary aspergillosis)

  • Chronic pulmonary aspergillosis, often in people with underlying lung damage

  • Subacute and acute invasive disease, particularly in immunocompromised or critically ill patients

Importantly, the review notes that aspergillosis is not limited to severely immunocompromised people. Chronic and subacute forms often occur in individuals with structural lung disease who are otherwise immunocompetent.

Climate change and emerging fungal risks

One of the most forward-looking sections of the paper addresses how climate change and natural disasters are altering fungal disease patterns. Rising environmental temperatures, flooding, storms and environmental disruption are:

  • Increasing exposure to environmental fungi

  • Enabling fungi to adapt to higher temperatures

  • Contributing to outbreaks after natural disasters and trauma

  • Expanding fungal diseases into new geographic regions

The authors argue that fungal infections must be considered part of future public health and healthcare resilience planning.

Key take-home messages

  • Systemic fungal infections are time-critical medical emergencies

  • Diagnosis usually requires multiple tests, not a single result

  • Early antifungal treatment is often necessary — but must be reviewed

  • Diagnostics are essential for safe antifungal stewardship

  • Antifungal resistance is a real and growing problem

  • Climate change is reshaping fungal epidemiology and risk

Free access to the full article

Elsevier has provided free access to the full paper for a limited time (no registration required):

👉 https://authors.elsevier.com/a/1mZqR4qdNoJLH2
🗓️ Available until 28 March 2026

This article is recommended reading for patients wanting a deeper understanding of fungal disease, as well as clinicians, microbiology teams, and healthcare planners.

by GAtherton

Can blood tests help predict if chronic pulmonary aspergillosis will come back?

This study from the National Aspergillosis Centre (NAC) looked at people with chronic pulmonary aspergillosis (CPA) who had completed antifungal treatment and asked a simple question:

Can blood tests tell us who is more likely to relapse after treatment stops?

What the researchers did

Doctors reviewed patients with CPA who had:

  • Taken antifungal treatment for at least 6 months

  • Stopped treatment because they were clinically stable

They then followed these patients to see who stayed well and who relapsed, and compared this with their blood test results at the time treatment stopped.

What they found

  • About 1 in 4 patients had a relapse after stopping treatment

  • People whose Aspergillus IgG blood test was still high at the end of treatment were much more likely to relapse

  • Patients whose IgG level had fallen to a lower level did not relapse in this study

  • Signs of Aspergillus allergy or sensitisation also increased relapse risk

  • CT scan appearances and treatment length alone were not reliable predictors

Why this matters for patients

This means that:

  • Blood tests may help doctors decide when it is safe to stop treatment

  • Some people may need closer follow-up or longer treatment

  • Follow-up can be more personalised, rather than “one size fits all”

Importantly, a relapse does not mean treatment failed — it reflects how persistent this infection can be in damaged lungs.

Key takeaway

A simple blood test at the end of treatment may help predict who needs closer monitoring for CPA relapse.

This research supports a more individualised approach to long-term CPA care.

by GAtherton

Wearable devices and aspergillosis

Are they useful yet – and which ones are the most accurate?

The short answer

Wearable devices do not diagnose aspergillosis and cannot tell what is causing symptoms.
However, some wearables are now good enough to provide useful background information about how your body is coping over time.

Their value lies in:

  • spotting gradual deterioration

  • recognising patterns over weeks or months

  • supporting conversations with your clinical team

They are not a replacement for scans, blood tests, sputum cultures, lung function tests, or specialist review.

What wearables can realistically help with

For people with:

  • Chronic Pulmonary Aspergillosis (CPA)

  • Allergic Bronchopulmonary Aspergillosis (ABPA)

  • Aspergillus bronchitis

  • Aspergillosis with bronchiectasis or asthma

wearables can sometimes help answer:

  • “Am I slowly getting worse, or is this just a bad patch?”

  • “Has my recovery from exertion changed?”

  • “Are my nights becoming more disrupted?”

They are most useful for long-term trends, not day-to-day decisions.

The signals that matter most

From both patient experience and respiratory clinical practice, these signals tend to be most meaningful:

1. Activity tolerance

  • Falling step count over weeks

  • Needing longer to recover after usual activity

  • Avoiding activity you previously managed

➡ Often one of the earliest signs of deterioration.

2. Resting heart rate

  • A persistent rise from your own baseline

  • Especially if not explained by infection, fever, medication or stress

➡ Often reflects physiological strain before symptoms become obvious.

3. Sleep quality

  • Frequent night waking

  • Shortened or fragmented sleep

  • Feeling unrefreshed despite enough hours in bed

➡ Poor sleep often accompanies worsening respiratory symptoms or medication effects.

4. Oxygen saturation (SpO₂) trends

  • Repeated low readings

  • Drops overnight or with exertion

  • Patterns that persist over days or weeks

➡ Trends matter far more than single readings.
➡ Dedicated oxygen monitors are usually more reliable than watches.

What about ECG and breathing rate?

These features are often misunderstood. They are not useless, but they are supportive rather than central in aspergillosis care.

ECG (heart rhythm)

Some wearables can record a single-lead ECG, which may detect:

  • atrial fibrillation

  • sustained rhythm abnormalities

This can be helpful if someone develops:

  • new palpitations

  • breathlessness out of proportion to lung symptoms

  • dizziness or faintness

➡ ECG does not provide information about Aspergillus activity or lung disease progression.

Breathing (respiratory) rate

Most wearables estimate breathing rate indirectly, usually during sleep.

Breathing-rate trends may:

  • support a sense that breathing effort has increased

  • highlight disrupted sleep linked to respiratory load

➡ It cannot distinguish fungal disease from asthma, infection, anxiety or medication effects.

Medication and age matter — a lot

When clinicians interpret wearable data, they always consider:

  • antifungal medicines (e.g. azoles)

  • steroids (current or past)

  • asthma and allergy treatments

  • other long-term conditions

  • age-related physiological change

Common medication effects seen on wearables

  • higher resting heart rate

  • poorer sleep

  • fatigue

  • reduced activity tolerance

These are common and expected and do not automatically mean disease progression.

As we age:

  • recovery slows

  • sleep becomes lighter

  • heart-rate variability reduces

  • oxygen dips more easily overnight

➡ Always compare data to your own baseline, not to “normal” values.

Environment and everyday factors strongly affect readings

Often more than lung disease itself

Wearables measure signals through the skin and movement, not directly from the lungs.

This makes them highly sensitive to environment and daily circumstances.

Many “abnormal” readings reflect conditions around you, not worsening aspergillosis.

Temperature (especially cold)

Cold causes blood vessels in the skin to narrow, which can lead to:

  • falsely low oxygen readings

  • erratic heart-rate data

  • missing or failed measurements

Common situations:

  • cold bedrooms

  • winter walks

  • sleeping with arms outside the duvet

➡ A low oxygen reading in the cold is often technical, not medical.

Altitude and air pressure

At higher altitude (even modest):

  • oxygen saturation normally falls

  • breathing rate may rise

  • sleep may worsen

Examples:

  • flying

  • holidays in hilly or mountainous areas

  • high-rise accommodation

➡ This is normal physiology, not disease progression.

Air quality, humidity and heat

Poor air quality or high humidity can cause:

  • faster breathing

  • increased heart rate

  • worse sleep

  • reduced activity tolerance

➡ Wearables detect body stress, not its cause.

Sleep environment

Sleep data is very sensitive to:

  • noise

  • light

  • room temperature

  • uncomfortable bedding

A poor sleep score often reflects environmental disruption, not lung decline.

Movement, posture and coughing

Night-time data can be affected by:

  • coughing

  • restless sleep

  • sleeping on the arm wearing the device

➡ Night data is often noisy and imperfect.

Hydration, alcohol and meals

  • dehydration → higher heart rate

  • alcohol → worse sleep and altered breathing rate

  • heavy evening meals → raised heart rate

These effects are temporary and not signs of deterioration.

Stress and anxiety

Stress can:

  • raise heart rate

  • increase breathing rate

  • worsen sleep

Wearables cannot distinguish stress from illness, and worrying about readings can make readings worse — a common feedback loop.

What wearables cannot do (important)

  • They cannot diagnose aspergillosis

  • They cannot identify fungal flares

  • They cannot separate cause from effect

  • They cannot replace specialist investigations

They provide context, not answers.

The most accurate consumer devices (2025–26)

Best overall smartwatches

  • Apple Watch (Series 9 / Ultra 2) – excellent heart-rate accuracy, ECG, good sleep trends

  • Withings ScanWatch 2 – health-focused, ECG and oxygen, long battery life

  • Garmin Venu 3 / Epix Pro – excellent activity and recovery tracking

Best non-watch wearables

  • Oura Ring (Gen 3) – strong overnight physiology and sleep trends

  • Wellue O2Ring / similar continuous oximeters – more reliable oxygen trends than watches

These are listed because of better accuracy and consistency, not because they are diagnostic devices.

Can wearable data cause over-worry?

Yes — and this is common, especially in people with long-term lung disease.

Wearables can sometimes:

  • increase anxiety

  • encourage constant checking

  • turn normal variation into worry

  • make people feel unwell even when stable

This is not a personal weakness.

When wearables help

  • checked occasionally

  • viewed over weeks or months

  • used to support (not replace) symptoms

When wearables stop helping

  • if they increase anxiety

  • if they disrupt sleep

  • if numbers override how you feel

➡ It is entirely reasonable to reduce use or stop.

How specialists actually prioritise information

In real aspergillosis care, clinicians still focus on:

  1. How you feel

  2. What you can do

  3. Symptoms and sputum

  4. Imaging and tests

  5. Medication history

Wearable data sits well below these.

The bottom line

  • ✔ Wearables are becoming useful for monitoring trends

  • ✔ ECG and breathing rate add context and safety, not answers

  • ✔ Medication, age and environment strongly affect readings

  • ❌ Wearables do not diagnose aspergillosis

  • ✔ If a device increases anxiety, stepping back is sensible

by GAtherton

How the Body Handles Chemicals, Medicines, and Antifungals

Why metabolism differs between people — and why this matters in aspergillosis

The big idea (in one sentence)

Your body uses an ancient liver detox system to handle chemicals from food, air, and medicines — and differences in that system explain why people with aspergillosis respond so differently to antifungal drugs.

What is metabolism?

Every day, your body is exposed to chemicals from many sources:

  • Food and drink

  • Air pollution and moulds

  • Natural plant chemicals

  • Hormones your body makes itself

  • Medicines, including antifungals and steroids

Many of these chemicals cannot be safely removed in their original form.
They first need to be chemically modified so they can be excreted in urine or bile.

This process is called metabolism, and it happens mainly in the liver.

The liver’s chemical processing system

The liver contains a large family of enzymes called cytochrome P450, often shortened to CYP.

Important clarification

  • CPA = Chronic Pulmonary Aspergillosis (a lung disease)

  • CYP = Cytochrome P450 (liver enzymes)

They sound similar but are completely different things.

What CYP enzymes really do

CYP enzymes did not evolve to deal with medicines.
They evolved to protect us from chemicals in the environment.

They help process:

  • Plant toxins and food chemicals

  • Smoke and air pollution

  • Mould and fungal by-products

  • Alcohol and caffeine

  • Hormones such as cortisol and sex hormones

  • Medicines (which are treated as “foreign chemicals”)

Medicines simply use a system that already existed.

How CYP enzymes “recognise” chemicals

CYP enzymes do not recognise chemicals like the immune system recognises germs.

Instead, they recognise chemical patterns, such as:

  • Fat-solubility (hard to excrete)

  • Size and shape

  • Reactive chemical groups

If a molecule:

  • Fits into the enzyme’s binding pocket, and

  • Can be chemically modified,

then CYP will act on it.

This makes CYP enzymes:

  • Broad (they work on many substances)

  • Flexible

  • Imperfect by design

The two main stages of metabolism (simplified)

Stage 1 – Modification

  • Mainly done by CYP enzymes

  • The chemical is altered (often oxidised)

  • This may:

    • Reduce activity

    • Prepare it for removal

    • Occasionally create a more toxic intermediate

Stage 2 – Packaging for removal

  • The altered chemical is “tagged”

  • It becomes water-soluble

  • It can now leave the body safely

Why metabolism differs between people

This is especially important for aspergillosis patients.

1. Genetics (the biggest factor)

People inherit different versions of CYP enzymes.

Some people:

  • Break drugs down slowly → higher levels → side effects

  • Break drugs down quickly → low levels → reduced effectiveness

Two people on the same antifungal dose can have very different blood levels.

2. Other medicines

Some medicines:

  • Block CYP enzymes (slowing breakdown)

  • Speed up CYP enzymes (lowering drug levels)

Antifungals, steroids, antibiotics, antidepressants, and heart drugs often interact.

3. Inflammation and chronic illness

During infection or chronic inflammation:

  • CYP activity is often reduced

  • Drug levels may rise unexpectedly

This matters in:

  • Chronic Pulmonary Aspergillosis (CPA)

  • Allergic Bronchopulmonary Aspergillosis (ABPA)

  • Bronchiectasis

  • Severe asthma

Drug handling can change during disease flares.

4. Liver health and age

  • Liver disease can slow metabolism

  • Older adults often process drugs differently

Why something can become a “poison”

A substance can cause harm if it:

  • Escapes CYP processing

  • Is metabolised too slowly

  • Overwhelms the system at high dose

  • Blocks CYP so other substances build up

  • Is converted into a toxic by-product

This explains:

  • Why some foods are toxic to dogs but safe for humans

  • Why “natural” substances are not automatically safe

  • Why dose really matters

A key question:

Why not design medicines that CYP can’t break down?

This is a real goal in drug development, and your instinct is correct.

If a drug:

  • Is broken down very slowly, or

  • Avoids CYP metabolism altogether,

then:

  • It stays in the body longer

  • Blood levels are steadier

  • Fewer doses are needed

This is why some medicines are once-daily, once-weekly, or long-acting injections.

But there is a trade-off

CYP metabolism is not just an inconvenience — it is also a safety system.

If a drug:

  • Cannot be metabolised, and

  • Cannot be excreted easily,

then:

  • It may accumulate

  • Side effects last much longer

  • Toxicity is harder to reverse

  • Stopping the drug does not stop the problem quickly

So completely avoiding CYP can increase long-term risk, especially when medicines are taken for months or years.

How drug designers manage this balance

Most modern drugs aim for a middle ground:

  • Broken down slowly, not zero

  • More predictable metabolism

  • Fewer interactions with major CYP enzymes

  • Alternative clearance routes where possible

  • Long-acting formulations (slow release, depots) rather than permanent persistence

In other words:

Long enough to work — but short enough to stay safe

Why this is especially relevant in aspergillosis

Antifungal drugs are particularly challenging because:

  • Fungi are biologically similar to humans

  • Drugs often interact with human CYP enzymes

  • Treatment is long-term

  • Patients often take multiple other medicines

Because of this:

  • Blood level monitoring is common

  • Dose adjustments are expected

  • Side effects do not mean failure

  • Low levels do not mean non-compliance

This variability reflects normal biology, not poor care.

A simple way to think about it

  • Your liver is a chemical processing plant

  • CYP enzymes are general-purpose machines

  • Everyone’s machines run at slightly different speeds

  • Illness and other drugs change how they behave

  • Antifungals depend on these machines being “just right”

Key take-home messages for patients

  • CYP enzymes are part of your body’s everyday detox system

  • They evolved to handle food chemicals, pollution, moulds, and hormones

  • Medicines use the same system

  • People differ because of genetics, illness, and other drugs

  • In aspergillosis, variable drug levels are expected

  • Monitoring and dose adjustment are signs of good specialist care

  • Drugs are not designed to avoid metabolism completely — safety matters as much as convenience

by GAtherton

Antifungal Medicines: Dosing, Monitoring, and the Role of Specialist Care

A detailed reference for patients and non-specialist clinicians

1. Why antifungal treatment is different from most medicines

Oral antifungal medicines—especially azole antifungals—are essential for treating long-term fungal diseases such as chronic pulmonary aspergillosis and allergic bronchopulmonary aspergillosis.

They differ from many common medicines because they:

  • Have a narrow margin between effectiveness and toxicity

  • Behave very differently between individuals

  • Are often taken for months or years, not days

  • Interact with many commonly prescribed drugs

For these reasons, antifungal treatment requires individualised dosing, monitoring, and specialist input, rather than a standard fixed dose.

2. What “pharmacokinetics” means (plain language)

Pharmacokinetics describes what the body does to a drug:

  1. Absorption – how well the drug enters the bloodstream from the gut

  2. Distribution – how effectively it reaches tissues such as the lungs

  3. Metabolism – how quickly the liver breaks it down

  4. Elimination – how the drug leaves the body

Differences at any of these stages explain why the same dose can be ineffective for one person and toxic for another.

3. Different generations of azole antifungals behave differently

Each generation of azole antifungal was designed to improve effectiveness, but chemical changes also altered how the body handles the drug.

First-generation azoles (older drugs)

Examples

  • Ketoconazole

  • Fluconazole (limited activity against Aspergillus)

Key features

  • Variable absorption

  • Shorter half-life

  • Less reliable lung penetration

Clinical relevance

  • Rarely used now for chronic aspergillosis

Second-generation azoles (mainstay treatment)

Examples

  • Itraconazole

  • Voriconazole

  • Posaconazole

Key features

  • Excellent lung and tissue penetration

  • Highly variable metabolism between people

  • Strong interaction with liver enzymes

Clinical relevance

  • Very effective

  • Blood levels vary widely

  • Dose adjustment and monitoring are often essential

Newer azoles

Example

  • Isavuconazole

Key features

  • More predictable absorption

  • Long, stable half-life

  • Fewer extreme peaks and troughs

Clinical relevance

  • Often better tolerated long-term

  • Monitoring still important, but dosing may be more stable

4. Why the “right dose” matters so much

Too little antifungal

  • Infection not adequately controlled

  • Symptoms persist or worsen

  • Risk of antifungal resistance

  • Fewer future treatment options

Too much antifungal

  • Liver irritation or damage

  • Nausea, appetite loss

  • Neurological or visual side effects

  • Drug accumulation, especially with long-term use

The aim is always the lowest dose that effectively controls the fungus.

https://ars.els-cdn.com/content/image/3-s2.0-B9780123868824000189-f18-07-9780123868824.jpg

5. How clinicians know whether the dose is right

No single test determines this. The correct dose is identified when three elements align:

1️⃣ Blood level testing (therapeutic drug monitoring)

  • Measures how much drug is actually in the bloodstream

  • Helps identify:

    • Under-dosing

    • Target-range dosing

    • Toxic levels

2️⃣ Clinical response

  • Symptoms stabilise or improve

  • Fewer flare-ups or complications

  • Better day-to-day function

3️⃣ Safety monitoring

  • Liver and kidney blood tests

  • Review of side effects

  • Ongoing assessment of drug interactions

Only when effectiveness and safety are both acceptable is the dose considered “right”.

6. Why the right dose can change over time

A dose that was correct initially may later need adjustment because of:

  • Weight or body-composition changes

  • Age-related metabolic changes

  • New medications (including antibiotics or steroids)

  • Changes in liver or kidney function

  • Gradual drug accumulation during long-term therapy

Regular review is therefore expected and appropriate.

7. Is it sometimes impossible to find a stable dose?

Yes. For a minority of patients, a perfectly balanced dose cannot be found.

Reasons include:

  • Extremely fast or slow drug metabolism

  • A very narrow safety window

  • Long-term toxicity despite “acceptable” blood levels

  • Unavoidable interacting medications

  • Liver, kidney, or neurological vulnerability

  • Partial or full antifungal resistance

In these cases, the dose that controls the fungus and the dose that causes side effects may overlap.

This reflects biological limits, not treatment failure.

8. What clinicians do when a stable dose cannot be achieved

Options may include:

  • Switching to a different azole with different pharmacokinetics

  • Using modified dosing schedules (split dosing, slower titration)

  • Accepting a lower suppressive dose rather than full eradication

  • Considering non-azole antifungals where appropriate

  • Prioritising symptom control and quality of life

All are intentional, safety-focused decisions.

9. The central role of the specialist pharmacist

Specialist pharmacists are key to safe antifungal care, particularly for long-term azole therapy.

They play a critical role in:

Interpreting drug levels

  • Assessing whether a level is truly low or high

  • Accounting for dose timing and formulation

  • Preventing unnecessary or unsafe dose changes

Managing drug–drug interactions

Azoles interact with many common medicines, including:

  • Steroids and inhalers

  • Heart rhythm drugs

  • Blood thinners

  • Anti-epileptics

  • Pain medications

The specialist pharmacist:

  • Reviews the full medication list

  • Anticipates interactions before harm occurs

  • Advises on adjusting both interacting drugs

Individualising dosing

When standard doses do not work, they help design:

  • Non-standard doses

  • Split dosing schedules

  • Slow titration plans

  • Alternative azoles with different pharmacokinetics

Protecting patients during long-term treatment

They monitor:

  • Trends in liver and kidney tests

  • Signs of cumulative toxicity

  • Whether symptoms may be drug-related rather than disease-related

Coordinating care

They act as a bridge between:

  • Laboratory results

  • Clinical decision-making

  • Patient experience

https://www.omnicare.com/wp-content/uploads/omnicare-services-overview-02-expert-consultant.jpg

Their involvement often changes management, not just fine-tunes it.

10. Where antifungal drug level testing is done in the UK

In the UK, antifungal drug level testing is centralised.

  • Blood samples are taken locally

  • Samples are sent to specialist reference laboratories, most commonly the
    Mycology Reference Centre Manchester

  • Results are returned to the local clinical team for interpretation

Patients managed through specialist services such as the
National Aspergillosis Centre
benefit from integrated expertise in antifungal pharmacology, imaging, and long-term monitoring.

This process is routine and standard for antifungal care.

11. Key reassurance for patients

  • Dose changes are normal and expected

  • Side effects are often biology-driven, not your fault

  • Blood tests make treatment safer, not riskier

  • Switching drugs is a planned strategy, not giving up

12. One-paragraph summary

Antifungal medicines—particularly azole antifungals—have complex and highly variable behaviour in the body, with a narrow balance between effectiveness and toxicity. Safe use requires individualised dosing, therapeutic drug monitoring, symptom review, and long-term safety checks. Specialist pharmacists play a central role in interpreting drug levels, managing interactions, and tailoring treatment. For some patients, a perfectly balanced dose cannot be achieved, and alternative strategies are required. This reflects biological complexity, not failure, and the overarching aim is always effective fungal control with the best possible long-term safety and quality of life.

by GAtherton

Airways mucus and aspergillosis

A clear, patient-friendly explainer

People living with aspergillosis often say that mucus is one of the hardest symptoms to manage — thick sputum, coughing fits, plugs that feel “stuck”, and flare-ups that seem to come out of nowhere. This explainer brings everything together in one place: what mucus is for, why aspergillosis causes so much of it, why it becomes abnormal, and what current and future treatments aim to do.

1. What is airway mucus and why do we need it?

Mucus is normal, healthy, and essential. Everyone produces it all the time.

Its main roles are to:

  • Trap inhaled particles (dust, spores, bacteria, pollution)

  • Protect the airway lining from drying and irritation

  • Support the immune system

  • Clear the lungs, using tiny moving hairs (cilia) that sweep mucus upwards so it can be swallowed or coughed out
    (this clearance system is called the mucociliary escalator)

In healthy lungs:

  • Mucus is thin

  • Produced in small amounts

  • Cleared without you noticing it

2. Why aspergillosis causes excessive mucus

In aspergillosis, the lungs are under ongoing stress. Several factors combine:

Persistent immune activation

The immune system keeps reacting to Aspergillus material in the airways. Even when the fungus is controlled, inflammation can persist.

Allergic-type inflammation (especially in ABPA)

Allergic immune responses strongly stimulate mucus-producing cells, leading to:

  • Large volumes of mucus

  • Very sticky or rubbery sputum

Airway damage

Conditions commonly associated with aspergillosis (such as bronchiectasis or long-standing asthma) cause:

  • Widened or damaged airways

  • Poor mucus clearance

  • Pools of mucus that are hard to shift

Slowed clearance

Inflammation and infection impair cilia, so mucus:

  • Moves more slowly

  • Sits in the lungs longer

  • Becomes thicker and harder to clear

➡️ What starts as a protective response becomes a self-perpetuating problem.

3. Why thick mucus causes symptoms

Excess or abnormal mucus can:

  • Block airways → breathlessness and wheeze

  • Trigger coughing → especially overnight or on waking

  • Trap infection → repeated flare-ups

  • Reduce oxygen exchange

  • Increase fatigue and chest discomfort

Many patients describe it as:

“Glue-like”, “stringy”, “rubbery”, or “impossible to move”

4. Mucus plugs and crystals – why some mucus is so hard to clear

Mucus plugs

When mucus becomes very thick, it can:

  • Form plugs that partially or completely block airways

  • Show up on CT scans

  • Worsen breathlessness suddenly

Charcot–Leyden crystals

In allergic and eosinophilic airway disease (including allergic bronchopulmonary aspergillosis):

  • Breakdown products of allergic immune cells can form microscopic crystals

  • These crystals make mucus:

    • Stiffer

    • More irritating

    • Harder to clear

Their presence is a sign of ongoing allergic inflammation, not infection alone.

5. Why managing mucus really matters

Mucus is not just an inconvenience. Poor mucus control can:

  • Increase infection risk

  • Drive repeated exacerbations

  • Worsen lung damage over time

  • Reduce quality of life and sleep

  • Increase hospital admissions

For aspergillosis, mucus management is core treatment, not optional.

6. What helps now (current approaches)

A. Thin the mucus

  • Good hydration

  • Nebulised saline (normal or hypertonic)

  • Selected mucolytic medicines (used carefully)

B. Move it out

  • Regular airway clearance physiotherapy

  • Breathing techniques (e.g. active cycle breathing)

  • Oscillating devices (flutter, Acapella, Aerobika)

  • Gentle, regular physical activity where possible

C. Reduce inflammation

  • Inhaled corticosteroids (when appropriate)

  • Oral steroids (used cautiously)

  • Biologic therapies for selected allergic or eosinophilic disease

  • Antifungal treatment when fungal burden is contributing

D. Treat infections early

  • Bacterial infections thicken mucus further

  • Prompt treatment reduces long-term damage

7. What research is doing differently (emerging therapies)

Research is moving beyond simply “loosening mucus”.

1. Reducing mucus production at source

Scientists are developing drugs that aim to:

  • Switch off excessive mucus secretion

  • Preserve normal protective mucus

This targets the mucus-producing cells directly.

2. Blocking the signals that drive over-production

Inflammation sends chemical signals telling airways to make more mucus. New treatments aim to:

  • Calm allergic and immune pathways

  • Prevent expansion of mucus-producing cells

Some current biologic therapies already reduce mucus indirectly; future drugs will be more precise.

3. Changing mucus structure

Instead of thinning everything, researchers are studying ways to:

  • Loosen the internal “mesh” of mucus

  • Prevent dense plugs from forming

  • Restore normal movement by cilia

4. Targeting mucus crystals

In allergic aspergillosis, research is exploring how to:

  • Reduce crystal formation

  • Calm the specific immune responses that create them

5. New inhaled and physical approaches

Early trials are testing:

  • Inhaled therapies designed to mobilise secretions

  • Treatments that improve airflow behind mucus plugs

6. Precision medicine

Future mucus treatments are likely to be:

  • Personalised

  • Based on inflammation type, fungal involvement, airway damage, and immune markers

Two people with aspergillosis may have very different mucus drivers — and need different solutions.

8. What this means for patients today

  • There is no single “anti-mucus cure” yet

  • Promising therapies are in research and early trials

  • Safety and long-term effects must be proven first

For now:

  • Regular airway clearance remains essential

  • Treating inflammation and infection promptly is crucial

  • Understanding why your mucus behaves as it does helps guide treatment

Key messages to remember

  • Mucus is normally protective

  • Aspergillosis turns a helpful system into a problem

  • Thick, sticky mucus reflects ongoing inflammation and airway damage

  • Crystals signal allergic involvement, not just infection

  • Research is moving toward preventing abnormal mucus formation, not just thinning it

by GAtherton

Does when I eat cause fat gain if I have adrenal insufficiency?

Many people with adrenal insufficiency worry that eating at the “wrong time” — especially later in the day — will automatically cause weight gain or “steroid belly”.
This is understandable, but it’s important to separate myths from what actually happens in the body.

https://cdn.media.amplience.net/i/dexcom/stelo-bg-levels-graph?fmt=auto&qlt=default&w=2000
https://www.zrtlab.com/media/3286/1-normal-cortisol-curve-2024.png?height=267&mode=max&width=357

What doctors mean by “glucose response”

When clinicians or researchers talk about glucose response, they mean:

How your blood sugar rises and falls after eating

It does not mean that sugar is instantly being turned into fat.

A rise in blood glucose after eating is normal and happens in everyone.

Does eating later in the day automatically turn food into fat?

No.

Fat gain does not happen because of a single meal or snack — or because you ate at a particular time.

In most people:

  • Carbohydrates are first used for energy

  • Extra glucose is stored as glycogen in muscles and liver

  • Only repeated excess intake over time contributes to fat gain

Eating in the evening does not automatically cause fat storage.

Where insulin fits in (without the fear)

Eating raises blood glucose, which triggers insulin.

Insulin:

  • Helps move glucose into cells

  • Replenishes energy stores

  • Temporarily pauses fat burning

This pause is normal and reversible.
Insulin does not automatically create body fat.

Fat gain happens when:

  • Total calorie intake is consistently higher than needs

  • Steroid replacement is higher than required

  • This pattern continues over weeks or months

Why people with adrenal insufficiency feel confused about this

With adrenal insufficiency:

  • Cortisol replacement is taken in doses, not continuously

  • Symptoms, stress, poor sleep, or illness can affect appetite and energy

  • Some people are prone to low blood sugar, especially later in the day

Because of this:

  • Rigid food timing rules can make symptoms worse

  • Skipping meals or avoiding evening snacks can increase fatigue, dizziness, or night-time symptoms

A safer way to think about meal timing

Instead of strict rules, think in patterns:

  • Some people feel best with:

    • Larger meals earlier in the day

    • Lighter evenings

  • Others need:

    • A small evening snack

    • Protein or fat to keep blood sugar stable overnight

Both can be correct.

What matters most is:

  • How you feel

  • Whether your energy is stable

  • Whether sleep and symptoms improve

What usually matters more than timing

For people with adrenal insufficiency, weight changes are most often related to:

  • Total daily steroid dose

  • Repeated or prolonged stress dosing

  • Reduced activity due to illness or fatigue

  • Menopause, ageing, or other medical conditions

Food timing plays a much smaller role.

Key reassurance

If a food timing rule makes you feel worse, it is not the right rule for you.

  • A single glucose rise does not cause fat gain

  • Eating later does not automatically lead to weight gain

  • Safety, symptom control, and adequate steroid replacement come first

Please remember

Never change steroid dose or meal patterns intended to prevent hypoglycaemia without medical advice.
Underdosing steroids is far more dangerous than eating at the “wrong” time.

Take-home message

Focus on stability, nourishment, and feeling well — not fear of timing.

by GAtherton